Text: S.2512 — 114th Congress (2015-2016)All Information (Except Text)

Text available as:

Shown Here:
Public Law No: 114-146 (04/19/2016)

 
[114th Congress Public Law 146]
[From the U.S. Government Publishing Office]



[[Page 130 STAT. 357]]

Public Law 114-146
114th Congress

                                 An Act


 
 To expand the tropical disease product priority review voucher program 
  to encourage treatments for Zika virus. <<NOTE: Apr. 19, 2016 -  [S. 
                                2512]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled, <<NOTE: Adding Zika 
Virus to the FDA Priority Review Voucher Program Act.>> 
SECTION 1. <<NOTE: 21 USC 301 note.>>  SHORT TITLE.

    This Act may be cited as the ``Adding Zika Virus to the FDA Priority 
Review Voucher Program Act''.
SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER 
                    PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS 
                    DISEASE.

    Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360n(a)(3)) is amended--
            (1) by redesignating subparagraph (R) as subparagraph (S);
            (2) in subparagraph (Q), by striking ``Filoviruses'' and 
        inserting ``Filovirus Diseases''; and
            (3) by inserting after subparagraph (Q) the following:
                    ``(R) Zika Virus Disease.''.

    Approved April 19, 2016.

LEGISLATIVE HISTORY--S. 2512:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 162 (2016):
            Mar. 17, considered and passed Senate.
            Apr. 12, considered and passed House.

                                  <all>